Biotech drugmakers get 12-year protection in House health bill
The House health reform bill unveiled on Thursday would grant brand-name biotech-drug manufacturers 12 years of exclusivity before generic versions of their products can rely on their safety and efficacy data. The bill also would require drug makers to pay an estimated $60 billion in Medicare reimbursements over the next 10 years and allow the federal government to negotiate prices directly with companies.
Wall Street Journal, The | 10/30
This story published in BIO SmartBrief on 10/30/2009
More from SmartBrief:
Sen. Reid's bill would add 6 months' protection for biotech drugs
Monday, November 23, 2009
Generics firms oppose higher rebates in Sen. Baucus' health bill
Friday, September 18, 2009
House panel passes amendment that restricts comparative research
Friday, July 31, 2009
Get stories like these delivered daily for FREE:
|
BIO SmartBrief
Designed specifically for biotechnology industry professionals like you, BIO SmartBrief is a FREE daily e-mail newsletter. It provides the latest news and information you need to stay informed about important biotech issues. Learn more |
|